Retrospective analysis of the progression of a case of metastatic castration-resistant prostate cancer with neuroendocrine differentiation:the patient was a 65 year old man with prostate adenocarcinoma on prostate bio...Retrospective analysis of the progression of a case of metastatic castration-resistant prostate cancer with neuroendocrine differentiation:the patient was a 65 year old man with prostate adenocarcinoma on prostate biopsy,Gleason 4+4 score=8,70%,ISUP4 group,localized invasion of nerves.Progressed to metastatic castration-resistant prostate cancer after 8 months of novel endocrine therapy,persistent elevated PSA after endocrine therapy,chemotherapy,and radiation,abdominal metastasis,brain metastasis,gastric metastasis,and staging as neuroendocrine differentiation after second prostate biopsy,which is a highly malignant subtype and has been concerned as a mechanism of resistance to targeted therapies.We discuss how to choose a more optimal treatment plan and outline the patient's diagnostic and therapeutic course.We provide a reflection for the clinical study of metastatic castration-resistant prostate cancer with neuroendocrine type.展开更多
Background:Previously,Xiaoyan decoction(XYD)has been found to have a potential anti-tumor effect in vitro.The aim of this study was to explore the effect of XYD in A549 lung carcinoma xenograft mouse model.Method:The ...Background:Previously,Xiaoyan decoction(XYD)has been found to have a potential anti-tumor effect in vitro.The aim of this study was to explore the effect of XYD in A549 lung carcinoma xenograft mouse model.Method:The A549 lung carcinoma xenograft mouse model were established and divided into control and experiment group.The dynamic growth of the xenograft tumors was observed and the immune cells such as T cell,regulatory T cell(Treg)were explored by Fluorescence-activated cell sorter(FACS)analysis.In this study,network pharmacology was used to screen the anti-cancer monomers in XYD,and their effect targets were also predicted.Result:The result showed that the tumor growth was inhibited and the percent of Treg was down-regulated(P<0.05).Ten drug monomers were screened to inhibit lung cancer cell proliferation and promote cell apoptosis through PI3K/Akt pathway.Conclusion:Our results suggested that XYD inhibited tumor growth and improved the immunity of A549 lung carcinoma xenograft mouse model.展开更多
基金co-first authors:Zeng-Feng Hanco-first authors/Corresponding to:Bin-Xu Sun,Department of Oncology,The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion.No.88 Changling Road,Xiqing District,Tianjin 300381,China.E-mail:sunbinxu@126.comCorresponding to:Shan-Qi Guo,Department of Oncology,The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion.No.88 Changling Road,Xiqing District,Tianjin 300381,China.E-mail:15022476737@163.com.
文摘Retrospective analysis of the progression of a case of metastatic castration-resistant prostate cancer with neuroendocrine differentiation:the patient was a 65 year old man with prostate adenocarcinoma on prostate biopsy,Gleason 4+4 score=8,70%,ISUP4 group,localized invasion of nerves.Progressed to metastatic castration-resistant prostate cancer after 8 months of novel endocrine therapy,persistent elevated PSA after endocrine therapy,chemotherapy,and radiation,abdominal metastasis,brain metastasis,gastric metastasis,and staging as neuroendocrine differentiation after second prostate biopsy,which is a highly malignant subtype and has been concerned as a mechanism of resistance to targeted therapies.We discuss how to choose a more optimal treatment plan and outline the patient's diagnostic and therapeutic course.We provide a reflection for the clinical study of metastatic castration-resistant prostate cancer with neuroendocrine type.
基金This work is supported by Tianjin Science&Technology Plan Projects(No.17ZXMFSY00190)Tianjin Traditional Chinese Medicine Research Project,Tianjin health and family planning commission(No.2017003)the National Natural Science Foundation of China(No.81403220).
文摘Background:Previously,Xiaoyan decoction(XYD)has been found to have a potential anti-tumor effect in vitro.The aim of this study was to explore the effect of XYD in A549 lung carcinoma xenograft mouse model.Method:The A549 lung carcinoma xenograft mouse model were established and divided into control and experiment group.The dynamic growth of the xenograft tumors was observed and the immune cells such as T cell,regulatory T cell(Treg)were explored by Fluorescence-activated cell sorter(FACS)analysis.In this study,network pharmacology was used to screen the anti-cancer monomers in XYD,and their effect targets were also predicted.Result:The result showed that the tumor growth was inhibited and the percent of Treg was down-regulated(P<0.05).Ten drug monomers were screened to inhibit lung cancer cell proliferation and promote cell apoptosis through PI3K/Akt pathway.Conclusion:Our results suggested that XYD inhibited tumor growth and improved the immunity of A549 lung carcinoma xenograft mouse model.
